The boom in weight-loss drugs may have transformed the obesity market, but Novo Nordisk’s CEO says the industry is still only scratching the surface with tens of millions of Americans potentially eligible for treatment. Novo Nordisk President and CEO Mike Doustdar joined FOX Business’ Cheryl Casone on "Mornings with Maria" to discuss the adoption of GLP-1 drugs, their potential economic impact and the company’s outlook for medicines, including Wegovy. TOM BRADY TEAMS WITH DIGITAL HEALTH FIRM EMED TO EXPAND GLP-1 WEIGHT LOSS MEDICATION ACCESS"There is a long runway still," he said. He used insulin, another product sold by Novo Nordisk, as an example of how dosage can vary with body size. "Then of course comes on top of that, the economical value that comes from people getting back to work healthier," Doustdar said.